Trial Profile
Clinical Trials Insight: 700016974
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Oct 2006
Price :
$35
*
At a glance
- Drugs Ranpirnase (Primary) ; Doxorubicin
- Indications Malignant-mesothelioma
- Focus Registrational; Therapeutic Use
- Sponsors Tamir Biotechnology
- 27 Oct 2006 New trial record.